BiotechTV

•

채널 • 5개의 프로그램

생명 과학

생명 과학

2025. 05. 08.
생명 과학

생명 과학

20시간 전
생명 과학

생명 과학

격주 업데이트
생명 과학

생명 과학

2월 2일
생명 과학

생명 과학

2025. 12. 19.

1월 15일

SF Healthcare Week: Alumis' CEO Martin Babler walks us through the two successful phase 3 trials the company announced for its TYK2 last week

He discusses the TYK2 landscape and describes why Alumis believes TYK2 can be a broad class in immunology.

1월 15일

•

13분
1월 22일

Analysts Thursdays: Clear Street Senior Biotech Analyst Kaveri Pohlman shares her take on biotech for 2026 and discusses her top picks

She discusses Arrivent Biopharma, Oruka Therapeutics, Jade Biosciences, Zura Bio, and Pavella Therapeutics.

1월 22일

•

17분
1월 16일

SF Healthcare Week: Cytokinetics CEO Robert Blum discusses the approval and impending launch of the cardiomyopathy therapy MYQORZO

He discussed the REMS, launch plans, market opportunity, payors, and the metrics that the company will offer publicly over time. Plus, previewing a key new data readout that will be coming in the second quarter of this year.

1월 16일

•

12분
2025. 12. 30.

William Blair Senior Biotech Analyst Andy Hsieh shares an overview of the obesity space heading into 2026

He discusses the recently approved Wegovy pill, and compares and contrasts it to other oral programs from Lilly, Structure, and Corbus. Plus, how is the amylin space looking compared to GLP-1s, and a preview of Viking's 2026.

2025. 12. 30.

•

33분
2025. 12. 08.

ASH 2025: Nurix CEO Arthur Sands discusses his company's BTK degrader data at ASH, and highlights the benefits of degraders more broadly in oncology and I&I

He describes two studies Nurix presented for bexobrutideg at ASH, and also discusses the pivotal DAYBreak study that has already been initiated. Plus, his take on today's STAT6 competitor data and how he feels about IRAK4.

2025. 12. 08.

•

17분
2025. 08. 15.

Biotech Direct: MassBio CEO Kendalle Burlin O'Connell and Seaport Therapeutics Founder & CEO Daphne Zohar discuss NIH funding, recent developments at FDA, and improving the public's view of science

In this inaugural episode of Biotech Direct, BiotechTV's new show that will share the biotech industry's perspective on policy and regulatory news, Kendalle Burlin O'Connell and Daphne Zohar discuss the strategic importance of biotech to the United States, share their thoughts on new FDA initiatives, and brainstorm ways to raise public awareness of the importance of science.

2025. 08. 15.

•

33분
2025. 09. 02.

John Maraganore and Clive Meanwell are launching Corsera Health out of stealth - which, through a combo of predictive diagnostics and an RNAi targeting PCSK9 and angiotensinogen, aims extend lifespans

Launched publicly today, and funded with $50M at this point, Corsera Health hopes to target those who are most at risk for atherosclerotic cardiovascular disease from an early age. The goal is to extend lives with an annual medicine by lowering LDL and blood pressure.

2025. 09. 02.

•

13분
2025. 08. 11.

Episode 24: Samsara Biocapital's Srini Akkaraju

The Founder & Managing Partner of Samsara Biocapital, Dr. Akkaraju describes his early move from Standford to industry and various investment firms he worked for before founding Samsara in 2016. He discusses how the firm invests in all stages of life sciences companies and why he believes patience is a key virtue.

2025. 08. 11.

•

1시간 13분
1월 12일

SF Healthcare Week: Beam's CEO John Evans shares an update on based editing for alpha-1 antitrypsin deficiency, sickle cell disease, and more

He discusses regulatory feedback the company has received that might allow it to earn an accelerated approval in antitrypsin deficiency. Plus, filing for sickle cell later this year, and how he thinks about new targets.

1월 12일

•

10분
2025. 05. 15.

ASGCT 2025: Physicians and scientists raced to make a bespoke gene editing therapy for an infant who urgently needed one in months - a first hand account, and what this means for drug development

As published in NEJM today, UPenn's Kiran Musunuru describes how the team used base editing in a matter of months to treat an infant with CPS1 deficiently, and his thoughts on what the learnings of this case are for drug development.

2025. 05. 15.

•

17분

BiotechTV covers the biotechnology sector through news, stories, podcasts, and educational videos.

웹사이트

BiotechTV

인기 프로그램

SF Healthcare Week: Alumis' CEO Martin Babler walks us through the two successful phase 3 trials the company announced for its TYK2 last week

Analysts Thursdays: Clear Street Senior Biotech Analyst Kaveri Pohlman shares her take on biotech for 2026 and discusses her top picks

SF Healthcare Week: Cytokinetics CEO Robert Blum discusses the approval and impending launch of the cardiomyopathy therapy MYQORZO

William Blair Senior Biotech Analyst Andy Hsieh shares an overview of the obesity space heading into 2026

ASH 2025: Nurix CEO Arthur Sands discusses his company's BTK degrader data at ASH, and highlights the benefits of degraders more broadly in oncology and I&I

Biotech Direct: MassBio CEO Kendalle Burlin O'Connell and Seaport Therapeutics Founder & CEO Daphne Zohar discuss NIH funding, recent developments at FDA, and improving the public's view of science

John Maraganore and Clive Meanwell are launching Corsera Health out of stealth - which, through a combo of predictive diagnostics and an RNAi targeting PCSK9 and angiotensinogen, aims extend lifespans

Episode 24: Samsara Biocapital's Srini Akkaraju

SF Healthcare Week: Beam's CEO John Evans shares an update on based editing for alpha-1 antitrypsin deficiency, sickle cell disease, and more

ASGCT 2025: Physicians and scientists raced to make a bespoke gene editing therapy for an infant who urgently needed one in months - a first hand account, and what this means for drug development

소개

BiotechTV

인기 프로그램

인기 에피소드

소개